Study to Evaluate the Safety and Effectiveness of Withaferin A as a Treatment to Prevent GvHD in Transplant Patients

NCT07724873 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

RECRUITING

Status

54

Enrollment

OTHER

Sponsor class

Conditions

Hematopoietic Stem Cell Transplant (HSCT)
GVHD - Graft-Versus-Host Disease
Hematological Malignancy

Interventions

DRUG: SWA (standardized root extract of Withania somnifera)

Sponsor

Tata Memorial Centre

Collaborators

[object Object]